ResearcherFlinders UniversityNo recent work listed
Christos Stelios Karapetis
Matched on ORCID iD 0000-0003-1741-996X; OpenAlex author ID A5068720728. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2022: 2 papers · 2023: 1 paper
Papers 3
- ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001↗
- Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited int… Co-author DOI 10.1080/14737140.2022.2002689↗
- Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002065↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Timothy Jay Price · 3 shared papers, 2022–2023 · strength 0.39
- Paper Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperabl… DOI 10.1097/mpa.0000000000002065↗
- Paper Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestin… DOI 10.1080/14737140.2022.2002689↗
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001↗
- Amitesh Chandra Roy · 2 shared papers, 2022 · strength 0.26
- Paper Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperabl… DOI 10.1097/mpa.0000000000002065↗
- Paper Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestin… DOI 10.1080/14737140.2022.2002689↗
- Lorraine A. Chantrill · 2 shared papers, 2022–2023 · strength 0.25
- Paper Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestin… DOI 10.1080/14737140.2022.2002689↗
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001↗
- Niall Christopher Tebbutt · 2 shared papers, 2022–2023 · strength 0.25
- Paper Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestin… DOI 10.1080/14737140.2022.2002689↗
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001↗
- Nimit Singhal · 1 shared paper, 2022 · strength 0.14
- David Goldstein · 1 shared paper, 2022 · strength 0.13
- Florian Lordick · 1 shared paper, 2022 · strength 0.13
- Nick Pavlakis · 1 shared paper, 2022 · strength 0.13
- Eva Segelov · 1 shared paper, 2022 · strength 0.13
- Trevor Leong · 1 shared paper, 2022 · strength 0.13
- Adnan M. Nagrial · 1 shared paper, 2022 · strength 0.13
- Ian Chau · 1 shared paper, 2022 · strength 0.13
- Mike Nguyen · 1 shared paper, 2022 · strength 0.13
- Daniel John Renouf · 1 shared paper, 2022 · strength 0.13
- Andrew Peter Dean · 1 shared paper, 2023 · strength 0.12
- Joanna Lee · 1 shared paper, 2023 · strength 0.12
- Val Gebski · 1 shared paper, 2023 · strength 0.12
- Matthew Burge · 1 shared paper, 2023 · strength 0.12
- Chris Lomma · 1 shared paper, 2023 · strength 0.12
- Marion Harris · 1 shared paper, 2023 · strength 0.12
- Belinda Lee · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.